Ethos Financial Group LLC Has $430,000 Holdings in Pfizer Inc. (NYSE:PFE)

Ethos Financial Group LLC trimmed its stake in Pfizer Inc. (NYSE:PFE) by 11.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,933 shares of the biopharmaceutical company’s stock after selling 1,956 shares during the period. Ethos Financial Group LLC’s holdings in Pfizer were worth $430,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of PFE. Advantage Trust Co acquired a new stake in shares of Pfizer in the 4th quarter valued at $171,000. Heritage Investors Management Corp boosted its stake in shares of Pfizer by 6.3% in the 4th quarter. Heritage Investors Management Corp now owns 461,739 shares of the biopharmaceutical company’s stock valued at $13,293,000 after purchasing an additional 27,493 shares in the last quarter. US Asset Management LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at $403,000. OLD Republic International Corp boosted its stake in shares of Pfizer by 13.3% in the 4th quarter. OLD Republic International Corp now owns 1,614,700 shares of the biopharmaceutical company’s stock valued at $46,487,000 after purchasing an additional 190,000 shares in the last quarter. Finally, Breed s Hill Capital LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at $216,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Morgan Stanley boosted their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $36.00.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.07 during trading hours on Thursday, reaching $28.20. 47,806,405 shares of the stock were exchanged, compared to its average volume of 43,591,230. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock’s fifty day simple moving average is $26.94 and its 200 day simple moving average is $28.12. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The firm has a market capitalization of $159.66 billion, a price-to-earnings ratio of -469.59, a P/E/G ratio of 1.17 and a beta of 0.63.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The company had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same period last year, the firm earned $1.23 earnings per share. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.39 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 5.96%. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.